VEGF-A165 augments erythropoietic development from human embryonic stem cells

Area of Science:

• Stem cell biology
• Hematopoiesis research
• Developmental biology

Background:

• Hematopoietic cell fate in human embryonic stem cells (hESCs) can be augmented by cytokines and BMP-4.
• Factors regulating specific hematopoietic lineage commitment from hESCs remain largely unreported.

Purpose of the Study:

• To investigate the role of vascular endothelial growth factor (VEGF-A165) in directing hematopoietic lineage commitment from hESCs.
• To identify factors capable of regulating erythropoiesis in hESC-derived hematopoiesis.

Main Methods:

• Human embryonic stem cells (hESCs) were differentiated into embryoid bodies (EBs) in the presence of hematopoietic cytokines, BMP-4, and VEGF-A165.
• Flow cytometry and gene expression analysis were used to assess hematopoietic and erythroid marker expression.
• The effects on globin chain synthesis and self-renewal potential were evaluated.

Main Results:

• VEGF-A165 selectively promoted erythropoietic development from hESCs, dependent on cytokines and BMP-4.
• VEGF-A165 increased CD34+KDR+ cells and erythroid marker expression, including embryonic globins (zeta and epsilon).
• VEGF-A165 enhanced the self-renewal of primitive hematopoietic cells with erythroid progenitor capacity.

Conclusions:

• VEGF-A165 plays a significant role in promoting erythropoiesis during hESC differentiation.
• This study provides the first evidence for a factor regulating hematopoietic lineage development in hESCs.
• VEGF-A165 is a key regulator of erythroid commitment in hESC-derived hematopoiesis.